| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.13.12.1728 |
| P698 | PubMed publication ID | 8241092 |
| P2093 | author name string | E J Schaefer | |
| J M Ordovas | |||
| J Genest | |||
| J C Fruchart | |||
| J M Bard | |||
| P433 | issue | 12 | |
| P921 | main subject | coronary artery disease | Q844935 |
| hypoalphalipoproteinemia | Q5959167 | ||
| P304 | page(s) | 1728-1737 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Familial hypoalphalipoproteinemia in premature coronary artery disease | |
| P478 | volume | 13 |
| Q37288388 | A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. |
| Q44205520 | A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families |
| Q74341167 | Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels |
| Q37576113 | ApoB versus non-HDL-C: what to do when they disagree |
| Q28351795 | Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial |
| Q37835397 | Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. |
| Q40440943 | Clustering of cardiovascular risk factors: Targeting high-risk individuals |
| Q44329447 | Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol |
| Q74348218 | Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations |
| Q28067479 | Diagnosis and treatment of high density lipoprotein deficiency |
| Q31018798 | Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. |
| Q44300074 | Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells |
| Q24608464 | Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline |
| Q24792755 | Gene therapy for lipid disorders |
| Q58545602 | Genetic and secondary causes of severe HDL deficiency and cardiovascular disease |
| Q33993060 | Genetic causes of high and low serum HDL-cholesterol |
| Q77452737 | Genetics of lipoprotein disorders |
| Q37000080 | HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease |
| Q34107511 | High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis |
| Q35856884 | High-density lipoprotein subfractions and risk of coronary artery disease |
| Q34990624 | High-density lipoproteins and atherosclerosis |
| Q28645890 | How, when, and why to use apolipoprotein B in clinical practice |
| Q51552490 | Hypercholesterolemia and Dyslipidemia. |
| Q51537186 | Hypercholesterolemia and Dyslipidemia: Issues for the Clinician. |
| Q54053962 | Impaired HDL response to fat in men with coronary artery disease. |
| Q77452740 | Lipoproteins and atherogenesis |
| Q22010457 | Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency |
| Q46684197 | Prevalence of obesity and its association with cardiovascular disease risk factors in adolescent girls from a college in central Taiwan |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q36901653 | Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis |
| Q80231409 | Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature |
| Q33310999 | Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol |
| Q52595882 | The Design and Rationale of SAVE BC: The Study to Avoid Vascular Events in British Columbia. |
| Q73112125 | The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano |
| Q37049629 | The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis |
Search more.